🔬 Peer-Reviewed Pre-Clinical Evidence

The Science Behind MAMOSURE

Pre-clinical studies validated at India's top government research institutions — ACTREC (Tata Memorial Centre) and Haffkine Institute, Mumbai.

ACTREC — Tata Memorial CentreHaffkine Institute MumbaiInternational Patent ProtectedFSSAI Registered

Govt Research Institutions

Pre-Clinical Studies

10+

Years of Pharma Innovation

100%

Safe — Zero Toxicity to Normal Cells

Research Institutions

Our Validation Partners

Mamosure's formulation has been independently evaluated by two of India's most respected government research institutions.

🏥

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

Tata Memorial Centre, Navi Mumbai

India's foremost cancer research institution. ACTREC conducted pre-clinical evaluation of Mamosure's formulation on established breast cancer cell lines using standardised cytotoxicity assay methodology.

📄 References 1, 5

🔬

Haffkine Institute for Training, Research and Testing (HITRT)

Government of Maharashtra, Mumbai — Est. 1899

A Government of Maharashtra public health institution with over 125 years of scientific legacy. Confirmed zero toxicity to normal cells.

📄 Reference 2

How It Works

Mechanism of Action

Three mechanisms observed in pre-clinical laboratory cell-line studies of Mamosure's formulation. These are early-stage findings in cultured cells, not results in people.

Cell-Cycle Regulation

In these cell-line studies, the formulation was associated with G0/G1 and G2 cell-cycle arrest in MCF7 and MDA-MB-231 cultures.

Selective Apoptosis Induction

In these cell-line studies, apoptosis was observed in the cultured cells, with no toxicity to normal cells in the same assays.

Immune Effector Function

Pre-clinical evaluation indicated support for immune effector activity including NK cells and cytotoxic T-lymphocytes.

Pre-Clinical Evidence

Study Results

Three independent pre-clinical studies using globally recognised laboratory methods, conducted at India's top government research institutions.

Study 01

MCF7 Breast Cancer Cell Line

Hormone Receptor-Positive

Model

MCF7 — most widely studied oestrogen-receptor-positive human breast cancer cell line⁶

Method

MTT colorimetric cell viability assay + flow cytometry cell-cycle analysis⁵

Institute

ACTREC, Tata Memorial Centre, Navi Mumbai

✅ Findings: Statistically significant cytotoxicity; G0/G1 and G2 phase cell-cycle arrest observed.¹

Study 02

MDA-MB-231 Breast Cancer Cell Line

Triple-Negative (ER−/PR−/HER2−)

Model

MDA-MB-231 — aggressive triple-negative breast cancer cell line⁷

Method

MTT assay + Annexin V/PI apoptosis assay⁵

Institute

ACTREC, Tata Memorial Centre, Navi Mumbai

✅ Findings: Successful apoptosis induction and G0/G1 cell-cycle arrest confirmed.¹

Study 03

In-Vivo Safety & Toxicity Profile

In-Vivo Animal Model

Model

In-vivo animal model; conducted under standard toxicological protocols

Also noted

Immune effector function support observed

Institute

Haffkine Institute (HITRT), Mumbai

✅ Findings: Complete absence of cytotoxicity to normal healthy cells. No adverse effects at evaluated dosages.²

Regulatory & IP Status

Compliance & Protection

Mamosure is fully compliant with India's food safety regulations and protected by international intellectual property rights.

✅

FSSAI Registered Food Supplement

Mamosure is registered with the Food Safety and Standards Authority of India (FSSAI) as a food supplement.

🏛️

International Patent Protection

Mamosure's proprietary formulation is protected by patents granted in multiple countries covering the composition and method of preparation.

Scientific Citations

References

Institution Data on File. Pre-clinical cytotoxicity and cell-cycle studies of Mamosure on MCF7 and MDA-MB-231 breast cancer cell lines. ACTREC, Tata Memorial Centre, Navi Mumbai, India. Internal report — available on request.
Institution Data on File. Safety and toxicological evaluation of Mamosure. Haffkine Institute for Training, Research and Testing (HITRT), Mumbai, India. Internal report — available on request.
Journal Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1–2):72–79. doi: 10.1016/j.jep.2005.05.011
Journal Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi: 10.1080/01926230701320337
Journal Mosmann T. Rapid colorimetric assay for cellular growth and survival. J Immunol Methods. 1983;65(1–2):55–63. doi: 10.1016/0022-1759(83)90303-4
Journal Levenson AS, Jordan VC. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res. 1997;57(15):3071–3078. PMID: 9242428
Journal Cailleau R et al. Long-term human breast carcinoma cell lines of metastatic origin. In Vitro. 1978;14(11):911–915. doi: 10.1007/BF02616120